Compare ESI & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESI | CRL |
|---|---|---|
| Founded | 1922 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 8.0B |
| IPO Year | N/A | 2000 |
| Metric | ESI | CRL |
|---|---|---|
| Price | $25.52 | $175.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 15 |
| Target Price | $30.70 | ★ $190.15 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | $2,499,200,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $8.04 | $2.43 |
| P/E Ratio | $25.91 | ★ N/A |
| Revenue Growth | ★ 3.87 | N/A |
| 52 Week Low | $16.77 | $91.86 |
| 52 Week High | $28.62 | $203.01 |
| Indicator | ESI | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 55.70 |
| Support Level | $25.40 | $157.49 |
| Resistance Level | $26.37 | $180.95 |
| Average True Range (ATR) | 0.88 | 5.52 |
| MACD | 0.02 | 1.17 |
| Stochastic Oscillator | 54.13 | 82.83 |
Element Solutions Inc is a specialty chemicals company whose businesses supply a broad range of solutions that enhance the performance of products people use every day. The company's reportable segments are Electronics and Industrial & Specialty. The Electronics segment, which generates maximum revenue, researches, formulates, and sells specialty chemicals and process technologies for all types of electronics hardware, from complex printed circuit board designs to semiconductor packaging. This segment's wet chemicals for metallization, surface treatments, and solderable finishes form the physical circuitry pathways, and its assembly materials, such as solder, pastes, fluxes, and adhesives, join those pathways together.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.